Study of VOY-101 in Patients With Advanced Non-Neovascular Age-Related Macular Degeneration

Phase 1/2 Unknown 45 enrolled Perceive Biotherapeutics, Inc.

Non-randomizedSequentialQuadruple-blindTreatment

Summary

This safety study comprises a dose escalation study of VOY-101, followed by a cohort of subjects randomized to the maximum tolerated dose arm, a lower dose arm, and control arm.

Timeline

Start: 2022-11-17
Primary completion: 2025-11
Completion: 2025-11

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	VOY-101	Unknown	—	Intravitreal

Study of VOY-101 in Patients With Advanced Non-Neovascular Age-Related Macular Degeneration

Summary

Timeline

Drugs

Indications